Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAssessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Publication: JAMA Oncology
Design:
An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.
Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.